保険金収入、資本剰余金合計、試作品売却原価
- 【期間】
年度 | 保険金収入 | 資本剰余金合計 | 試作品売却原価 |
---|
2008/03 | - | | 2041億 | | - | |
2009/03 | - | | 2041億 | ±0% | - | |
2010/03 | - | | 2041億 | ±0% | - | |
2010/12 | - | | 2041億 | ±0% | - | |
2011/03 | - | | 2041億 | ±0% | - | |
2011/06 | - | | 2041億 | ±0% | - | |
2011/09 | - | | 2041億 | ±0% | - | |
2011/12 | - | | 2041億 | ±0% | - | |
2012/03 | - | | 2041億 | +0% | - | |
2012/06 | - | | 2041億 | ±0% | - | |
2012/09 | - | | 2041億 | +0% | - | |
2012/12 | - | | 2041億 | -0% | - | |
2013/03 | - | | 2041億 | ±0% | - | |
2013/06 | - | | 2041億 | ±0% | - | |
2013/09 | - | | 2041億 | ±0% | - | |
2013/12 | - | | 2041億 | ±0% | - | |
2014/03 | - | | 2041億 | ±0% | - | |
2014/06 | - | | 2041億 | ±0% | - | |
2014/09 | - | | 2041億 | ±0% | - | |
2014/12 | - | | 2041億 | ±0% | - | |
2015/03 | - | | 2041億 | ±0% | - | |
2016/03 | - | | 1356億 | -33.6% | - | |
2017/03 | - | | 1356億 | ±0% | - | |
2018/03 | - | | 1356億 | ±0% | - | |
2019/03 | - | | 1356億 | ±0% | - | |
2019/06 | - | | - | | - | |
2019/09 | - | | - | | - | |
2019/12 | - | | - | | - | |
2020/03 | - | | 1356億 | ±0% | - | |
2020/06 | - | | - | | - | |
2020/09 | - | | - | | - | |
2020/12 | - | | - | | - | |
2021/03 | 3.56億 | | 1356億 | ±0% | - | |
2021/06 | - | | - | | - | |
2021/09 | - | | - | | - | |
2021/12 | - | | - | | - | |
2022/03 | 24.7億 | +594.7% | 1356億 | ±0% | - | |
2022/06 | - | | - | | - | |
2022/09 | - | | - | | - | |
2022/12 | - | | - | | - | |
2023/03 | 20.8億 | -15.7% | 1356億 | ±0% | 213百万 | |
2023/06 | - | | - | | - | |
2023/09 | - | | - | | - | |
2023/12 | - | | - | | - | |
2024/03 | 12億 | -42.5% | 1356億 | ±0% | 955百万 | +348.4% |
2024/06 | - | | - | | - | |